Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> China Pharma Providers
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
China Pharma Providers
Type:
CRO-Preclinical
Title:
Frontier Biosciences Co Ltd
Chinese
CSertification:
n/a
International
Certification:
n/a
Primary Location:
Chongqing
China
Contact Info:
3/F, Biochem Pharmaceutical Park, Building I, No.70, Keyuansi Jie, Hi-Tech Development, Shiqiaopu, Chongqing 400041, China
Tel: +86 23 68885251; 68880506 Fax: +86 23 6888 7671
Email: dxie@frontierbiotech.com, hej@frontierbiotech.com
Webpage:
www.frontierbsi.com
www.frontierbiotech.com
HQ
Contact Info:
Frontier BioSciences, Inc.
Maryland 20874, USA
Tel: +1 301 515 5560; 204 372 2100 Fax: +1 301 515 5562
Email: bwong@frontierbsi.com
Additional
Contact Info:
n/a
Description:
Frontier BioSciences, Inc. is a U.S.-based company providing contract research services to pharmaceutical companies and other drug development organizations. With a full-fledged R&D operation in China, it is committed to delivering high quality research, rapid report turnaround, and competitively-priced preclinical and clinical drug development services.
US services provider Frontier Biosciences has bought a majority stake in a China-based preclinical contract research organisation (CRO). With this new deal, Frontier becomes a shareholder and partner in the National Chengdu Center for Safety Evaluation of Drugs (NCCSED) - a contract research lab specialised in drug safety evaluation. The move is designed to enable the firm to boost its preclinical capacity in China.
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit